Vaginal microbicides and the prevention of HIV transmission

The Lancet Infectious Diseases

Volumn 8, Issue 11, 2008, Pages 685-697

  Cutler, Blayne ^a   Justman, Jessica ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

'AMPHORA'; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ACIDFORM; C31G; CARBOPOL 974P; CARRAGEENAN; CELLACEFATE; CELLULOSE SULFATE; CYANOVIRIN N; DAPIVIRINE; DODECYL SULFATE SODIUM; EMTRICITABINE; ENFUVIRTIDE; INVISIBLE CONDOM; MICROBICIDE; N [3 [4 (3 BENZYL 1 ETHYL 5 PYRAZOLYL) 1 PIPERIDINYLMETHYL] 4 (3 FLUOROPHENYL)CYCLOPENTYL] N METHYLVALINE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NAPHTHALENE SULFONATE; NONOXINOL 9; PLACEBO; PLANT EXTRACT; PRANEEM; PRO 2000; PSC RANTES; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAVVY; SURFACTANT; TENOFOVIR; UNCLASSIFIED DRUG; VAGINAL MILIEU PROTECTOR; VIRAL ENTRY INHIBITOR; VIVAGEL;

ADD ON THERAPY; ANTIVIRAL ACTIVITY; CLINICAL RESEARCH; CLINICAL TRIAL; CYTOTOXICITY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GENE MUTATION; HEMAGGLUTINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; MENSTRUATION; MITOGENESIS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SEXUAL TRANSMISSION; SIDE EFFECT; SINGLE DRUG DOSE; VAGINA DISEASE; VAGINAL PRURITUS; VIRUS CELL INTERACTION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ADMINISTRATION, INTRAVAGINAL; ANTI-RETROVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; SURFACE-ACTIVE AGENTS; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 53949100884     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(08)70254-8     Document Type: Review

References (172)

1. UNAIDS, and WHO. AIDS epidemic update 2007. Geneva, Switzerland: UNAIDS/World Health Organization. http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2007/ (accessed Sept 10, 2008).
2. UNAIDS, and WHO. AIDS epidemic update 2004. Geneva, Switzerland: UNAIDS/World Health Organization. http://www.unaids.org/bangkok2004/report.html (accessed Sept 10, 2008).
3. Walker P.R., Worobey M., Rambaut A., Holmes E.C., and Pybus O.G. Epidemiology: sexual transmission of HIV in Africa. Nature 422 (2003) 679
4. McGowan I. Microbicides: a new frontier in HIV prevention. Biologicals 34 (2006) 241-255
5. DeGruttola V., Seeage G.R., Mayer K.H., and Horsburgh C.R. Infectiousness of HIV between homosexual partners. J Clin Epidemiol 42 (1989) 849-856
6. Peterman T.A., and Curran J.W. Sexual transmission of human immunodeficiency virus. JAMA 256 (1986) 2222-2226
7. Padian N.S., Shiboski S.C., and Jewell N.P. Female-to-male transmission of human immunodeficiency virus. JAMA 266 (1991) 1664-1667
8. Downs A.M., and De Vincenzi I. Probability of heterosexual transmission of HIV: relationship to the number of unprotected sexual contacts. J Acquir Immune Defic Syndr Hum Retrovirol 11 (1996) 388-395
9. Chakraboty H., Sen P.K., Helms R.W., et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS 15 (2001) 621-627
10. Vittinghoff E., Douglas J., Judson F., McKirnan D., MacQueen K., and Buchbinder S.P. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 150 (1999) 306-311
11. Wilson T.E., Massad L.S., Riester K.A., et al. Sexual, contraceptive, and drug use behaviors of women with HIV and those at high risk for infection: results from the Women's Interagency HIV Study. AIDS 13 (1999) 591-598
12. Mosher W.D., Chandra A., and Jones J. Sexual behavior and selected health measures: men and women 15-44 years of age, United States. Report No 362 (2002), National Center for Health Statistics, Hyattsville, MD
13. Powers K.A., Poole C., Pettifor A.E., and Cohen M.S. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 8 (2008) 553-563
14. Pilcher C.D., Tien H.C., Eron J.J., et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 189 (2004) 1785-1792
15. Wawer M.J., Gray R.H., Sewankambo N.K., et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 191 (2005) 1403-1409
16. Auvert B., Taljaard D., Lagarde E., Sobngwi-Tambekou J., Sitta R., and Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2 (2005) e298
17. Bailey R.C., Moses S., Parker C.B., et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369 (2007) 643-656
18. Gray R.H., Kigozi G., Serwadda D., et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369 (2007) 657-666
19. Soilleux E.J., and Coleman N. Expression of DC-SIGN in human foreskin may facilitate sexual transmission of HIV. J Clin Pathol 57 (2004) 77-78
20. Shattock R.J., Griffin G.E., and Gorodeski G.I. In vitro models of mucosal HIV transmission. Nat Med 6 (2000) 607-608
21. Hope TJ. Latest understanding of HIV sexual transmission. Microbicides 2008 Conference; New Delhi, India; Feb 24-27, 2008.
22. Dezzutti C.S., James V.N., Ramos A., et al. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob Agents Chemother 48 (2004) 3834-3844
23. Miller C.J., and Shattock R.J. Target cells in vaginal HIV transmission. Microbes Infect 5 (2003) 59-67
24. Hladik F., Sakchalathorn P., Ballweber L., et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26 (2007) 257-270
25. Sturm A.W., and Zanen H.C. Characteristics of Haemophilus ducreyi in culture. J Clin Microbiol 19 (1984) 672-674
26. Croughan W.S., and Behbehani A.M. Comparative study of inactivation of herpes simplex virus types 1 and 2 by commonly used antiseptic agents. J Clin Microbiol 26 (1988) 213-215
27. Yasin B., Pang M., Wagar E.A., and Lehrer R.I. Examination of Chlamydia trachomatis infection in environments mimicking normal and abnormal vaginal pH. Sex Transm Dis 29 (2002) 514-519
28. Klebanoff S.J., and Coombs R.W. Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission. J Exp Med 174 (1991) 289-292
29. Martin H.L., Richardson B.A., Nyange P.M., et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 180 (1999) 1863-1868
30. Sewankambo N., Gray R.H., Wawer M.J., et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 350 (1997) 546-550
31. Taha T.E., Hoover D.R., Dallabetta G.A., et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 12 (1998) 1699-1706
32. Kish-Catalone T.M., Lu W., Gallo R.C., and DeVico A.L. Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5. Antimicrob Agents Chemother 50 (2006) 1497-1509
33. Muciaccia B., Padula F., Gandini L., Lenzi A., and Stefanini M. HIV-1 chemokine co-receptor CCR5 is expressed on the surface of human spermatozoa. AIDS 19 (2005) 1424-1426
34. Berlier W., Bourlet T., Lawrence P., et al. Selective sequestration of X4 isolates by human genital epithelial cells: implication for virus tropism selection process during sexual transmission of HIV. J Med Virol 77 (2005) 465-474
35. Strathdee S.A., Hogg R.S., O'Shaughnessy M.V., Montaner J.S., and Schechter M.T. A decade of research on the natural history of HIV infection: part 2. Cofactors. Clin Invest Med 19 (1996) 121-130
36. Baleta A. Concern voiced over "dry sex" practices in South Africa. Lancet 352 (1998) 1292
37. Norvell M.K., Benrubi G.I., and Thompson R.J. Investigation of microtrauma after sexual intercourse. J Reprod Med 29 (1984) 269-271
38. Van Damme L., Ramjee G., Alary M., et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomized controlled trial. Lancet 360 (2002) 971-977
39. Shattock R.J., and Moore J.P. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 1 (2003) 25-34
40. Greenhead P., Hayes P., Watts P.S., Laing K.G., Griffin G.E., and Shattock R.J. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 74 (2000) 5577-5586
41. Pudney J., Quayle A.J., and Anderson D.J. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod 73 (2005) 1253-1263
42. Moriyama A., Shimoya K., Ogata I., et al. Secretory leukocyte protease inhibitor (SLPI) concentrations in cervical mucus of women with normal menstrual cycle. Mol Hum Reprod 5 (1999) 656-661
43. Agace W.W., Amara A., Roberts A.I., et al. Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation. Curr Biol 10 (2000) 325-328
44. Poles M.A., Elliot J., Taing P., Anton P.A., and Chen I.S. A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J Virol 75 (2001) 8390-8399
45. Amerongen H.M., Weltzin R., Farnet C.M., Michetti P., Haseltine W.A., and Neutra M.R. Transepithelial transport of HIV-1 by intestinal M cells: a mechanism for transmission of AIDS. J Acquir Immune Defic Syndr 4 (1991) 760-765
46. Neutra M.R. Interactions of viruses and microparticles with apical plasma membranes of M cells: implications for human immunodeficiency virus transmission. J Infect Dis 179 suppl 3 (1999) S441-S443
47. Roddy R.E., Zekeng L., Ryan K.A., Tamoufe U., Weir S.S., and Wong E.L. A controlled trial of nonoxynol-9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 339 (1998) 504-510
48. Lorenzo A. Cellegy stops Ghana HIV trial; broader plans moving ahead. BioWorld Today (Nov 9, 2005)
49. Feldblum P.J., Adeiga A., Bakare R., et al. Savvy vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 3 (2008) e1474
50. Alliance for Microbicide Development. Microbicide candidates and ancillary devices in planned and funded clinical trials summary as of September 2008. http://www.microbicide.org/galleries/clinical-trials/Microbicides.Planned.Funded.Clinical.Trials2Sept2008.pdf (accessed Sept 28, 2008).
51. Johansson E. Results of phase III Carraguard trial. Microbicides 2008 Conference; New Delhi, India; Feb 24-27, 2008.
52. Van Damme L., Govinden R., Mirembe F.M., et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 359 (2008) 463-472
53. Halpern V, Wang L, Obunge O, et al. Effectiveness of cellulose sulfate gel for prevention of HIV: results of the phase III trial in Nigeria. 4th IAS Conference; Sydney, Australia; July 22-25, 2007. Abstract LB WESS302.
54. Lacey C. Unacceptable side effects of a hyperosmolar vaginal microbicide in a Phase I trial. Microbicides 2008 Conference; New Delhi, India; Feb 24-27, 2008. Abstract B08-527.
55. Jiang Y.H., Emau P., Cairns J.S., et al. SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 21 (2005) 207-213
56. Bernstein D.I., Stanberry L.R., Sacks S., et al. Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob Agents Chemother 47 (2003) 3784-3788
57. Paull J, Chen M, Millwood I, et al. SPL7013 gel (VivaGel(TM)), a topical microbicide in development for prevention of HIV and genital herpes, shown to be well tolerated and comparable with placebo after seven days administration in healthy males. 4th IAS Conference; Sydney, Australia; July 22-25, 2007. Abstract TUAC1LB.
58. Bourinbaiar A.S., and Lee-Huang S. The efficacy of nonoxynol-9 from an in vitro point of view. AIDS 10 (1996) 558-559
59. Calis S., Yulug N., Sumnu M., Ayhan A., and Hincal A.A. A non-antibiotic antimicrobial mixture (C31G): evaluation of the antimicrobial efficiency of C31G on vaginal cultures. Boll Chim Farm 131 (1992) 335-338
60. Krebs F.C., Miller S.R., Malamud D., Howett M.K., and Wigdahl B. Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate. Antiviral Res 43 (1999) 157-173
61. Wyrick P.B., Knight S.T., Gerbig D.G., et al. The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro. Antimicrob Agents Chemother 41 (1997) 1335-1344
62. Thompson K.A., Malamud D., and Storey B.T. Assessment of the anti-microbial agent C31G as a spermicide: comparison with nonoxynol-9. Contraception 53 (1996) 313-318
63. Bax R., Douville K., McCormick D., Rosenberg M., Higgins J., and Bowden M. Microbicides-evaluating multiple formulations of C31G. Contraception 66 (2002) 365-368
64. Ballagh S.A., Baker J.M., Henry D.M., and Archer D.F. Safety of single daily use for one week of C31G HEC gel in women. Contraception 66 (2002) 369-375
65. Mauck C.K., Weiner D.H., Creinin M.D., Barnhart K.T., Callahan M.M., and Bax R. A randomized phase I vaginal safety study of three concentrations of C31G vs extra strength gynol II. Contraception 70 (2004) 233-240
66. Piret J., Desormeaux A., and Bergeron M.G. Sodium lauryl sulfate, a microbicide effective against enveloped and nonenveloped viruses. Curr Drug Targets 3 (2002) 17-30
67. Haineault C., Gourde P., Perron S., et al. Thermoreversible gel formulation containing sodium lauryl sulfate as a potential contraceptive device. Biol Reprod 69 (2003) 687-694
68. Roy S., Gourde P., Piret J., et al. Thermoreversible gel formulations containing sodium lauryl sulfate or n-lauroylsarcosine as potential topical microbicides against sexually transmitted diseases. Antimicrob Agents Chemother 45 (2001) 1671-1681
69. Trottier S, Omar RF, Desormeaux A, et al. Phase I clinical trial to evaluate the safety, tolerance and acceptability of the invisible condom when applied intravaginally to healthy female subjects. XIV International AIDS Conference; Barcelona, Spain; July 7-12, 2002. Abstract LbPp2212.
70. Omar RF. Phase I/II randomized, double-blinded, placebo-controlled trials on the safety, tolerance and acceptability of the invisible condom, a physical and chemical barrier vaginal gel against HIV, in healthy volunteers in Cameroon. Microbicides 2008 Conference; New Dehli, India; Feb 24-27, 2008. Abstract B01-86.
71. Martin L.S., McDougal J.S., and Loskoski S.L. Disinfection and inactivation of the human T lymphotropic virus type III/lymphadenopathy-associated virus. J Infect Dis 152 (1985) 400-403
72. Ongradi J., Ceccherini-Nelli L., Pistello M., Specter S., and Bendinelli M. Acid sensitivity of cell-free and cell-associated HIV-1: clinical implications. AIDS Res Hum Retroviruses 6 (1990) 1433-1436
73. O'Connor T.J., Kinchington D., Kangro H.O., and Jeffries D.J. The activity of candidate virucidal agents, low pH and genital secretions against HIV-1 in vitro. Int J STD AIDS 6 (1995) 267-272
74. Olmsted S.S., Dubin N.H., Cone R.A., and Moench T.R. The rate at which human sperm are immobilized and killed by mild acidity. Fertil Steril 73 (2000) 687-693
75. Achilles S.L., Shete P.B., Whaley K.J., Moench T.R., and Cone R.A. Microbicide efficacy and toxicity tests in a mouse model for vaginal transmission of Chlamydia trachomatis. Sex Transm Dis 29 (2002) 655-664
76. Zeitlin L., Hoen T.E., Achilles S.L., et al. Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm Dis 28 (2001) 417-423
77. Van de Wijgert J.H., Fullem A., Kelly C., et al. Phase I trial of the topical microbicide BufferGel: safety results from four international sites. J Acquir Immune Defic Syndr 26 (2001) 21-27
78. Mayer K.H., Peipert J., Fleming T., et al. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin Infect Dis 32 (2001) 476-482
79. Tabet S.R., Callahan M.M., Mauck C.K., et al. Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 gel: 3 randomized trials in healthy low-risk men and HIV-positive men. J Acquir Immune Defic Syndr 33 (2003) 476-483
80. Amaral E., Faundes A., Zaneveld L., Waller D., and Garg S. Study of the vaginal tolerance to Acidform, an acid-buffering, bioadhesive gel. Contraception 60 (1999) 361-366
81. Amaral E., Perdigao A., Souza M.H., et al. Vaginal safety after use of a bioadhesive, acid-buffering, microbicidal contraceptive gel (ACIDFORM) and a 2% nonoxynol-9 product. Contraception 73 (2006) 542-547
82. Schwartz J.L., Poindexter A., Schmitz S.W., Mauck C., and Callahan M.M. Male tolerance of ACIDFORM gel. Contraception 71 (2005) 443-446
83. Patton D.L., Sweeney Y.C., Antonio M.A., Rabe L.K., and Hillier S.L. Lactobacillus crispatus capsules: single-use safety study in the Macaca nemestrina model. Sex Transm Dis 30 (2003) 568-570
84. Antonio M.A., and Hillier S.L. DNA fingerprinting of Lactobacillus crispatus strain CTV-05 by repetitive element sequence-based PCR analysis in a pilot study of vaginal colonization. J Clin Microbiol 41 (2003) 1881-1887
85. Chang T.L., Chang C.H., Simpson D.A., et al. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci USA 100 (2003) 11672-11677
86. Rao S., Hu S., McHugh L., et al. Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proc Natl Acad Sci USA 102 (2005) 11993-11998
87. Lagenaur L.A., and Berger E.A. An anti-HIV microbicide comes alive. Proc Natl Acad Sci USA 102 (2005) 12294-12295
88. Hemmerling A., Potts M., Walsh J., et al. Lime juice as a candidate microbicide? An open-label safety trial of 10% and 20% lime juice used vaginally. J Womens Health 16 (2007) 1041-1051
89. Balzarini J., and Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet 369 (2007) 787-797
90. Schols D., Pauwels R., Desmyter J., and De C.E. Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. Virology 175 (1990) 556-561
91. Mitsuya H., Looney D.J., Kuno S., Ueno R., Wong-Staal F., and Broder S. Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science 240 (1988) 646-649
92. Moulard M., Lortat-Jacob H., Mondor I., et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 74 (2000) 1948-1960
93. Indevus Pharmaceuticals. PRO2000: product description (2006), Indevus Pharmaceuticals, Lexington, NA, USA
94. Keller M.J., Zerhouni-Layachi B., Cheshenko N., et al. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis 193 (2006) 27-35
95. Van Damme L., Wright A., Depraetere K., et al. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex Transm Infect 76 (2000) 126-130
96. Mayer K.H., Karim S.A., Kelly C., et al. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 17 (2003) 321-329
97. Joshi S., Dutta S., Bell B., et al. Documenting intermenstrual bleeding in a vaginal microbicide study: case reports and lessons learned. AIDS Res Hum Retroviruses 22 (2006) 294-296
98. Perotti M.E., Pirovano A., and Phillips D.M. Carrageenan formulation prevents macrophage trafficking from vagina: implications for microbicide development. Biol Reprod 69 (2003) 933-939
99. Coggins C., Blanchard K., Alvarez F., et al. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex Transm Infect 76 (2000) 480-483
100. Bollen L., Blanchard K., Kilmarx P.H., et al. No increase in cervicovaginal proinflammatory ctokines after Carraguard use in a placebo-controlled randomized clinical trial. J Acquir Immune Defic Syndr 47 (2008) 253-257
101. Van de Wijgert J.H., Braunstein S.L., Morar N.S., et al. Carraguard vaginal gel safety in HIV-positive women and men in South Africa. J Acquir Immune Defic Syndr 46 (2007) 538-546
102. Kilmarx P.H., van de Wijgert J., Chaikummao S., et al. Safety and acceptability of the candidate microbicide Carraguard in Thai women: findings from a phase II clinical trial. J Acquir Immune Defic Syndr 43 (2006) 327-334
103. Pistorius A.G., van de Wijgert J., Sebola M., et al. Microbicide trials for preventing HIV/AIDS in South Africa: phase II trial participants' experiences and psychological needs. SAHARA J 1 (2004) 78-86
104. Population Council. Trial shows anti-HIV microbicide is safe, but does not prove it effective (Feb 18, 2008). http://www.popcouncil.org/mediacenter/newsreleases/Carraguard_Findings.html (accessed Sept 28, 2008).
105. Wallace A.R., Teitelbaum A., Wan L., et al. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception 76 (2007) 53-56
106. Anderson R.A., Feathergill K.A., Diao X.H., et al. Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J Androl 23 (2002) 426-438
107. Su H., and Caldwell H.D. Sulfated polysaccharides and a synthetic sulfated polymer are potent inhibitors of Chlamydia trachomatis infectivity in vitro but lack protective efficacy in an in vivo murine model of chlamydial genital tract infection. Infect Immun 66 (1998) 1258-1260
108. Christensen N.D., Reed C.A., Culp T.D., et al. Papillomavirus microbicidal activities of high-molecular-weight cellulose sulfate, dextran sulfate, and polystyrene sulfonate. Antimicrob Agents Chemother 45 (2001) 3427-3432
109. Simoes J.A., Citron D.M., Aroutcheva A., et al. Two novel vaginal microbicides (polystyrene sulfonate and cellulose sulfate) inhibit Gardnerella vaginalis and anaerobes commonly associated with bacterial vaginosis. Antimicrob Agents Chemother 46 (2002) 2692-2695
110. Scordi-Bello I.A., Mosoian A., He C., et al. Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother 49 (2005) 3607-3615
111. Mauck C., Weiner D.H., Ballagh S., et al. Single and multiple exposure tolerance study of cellulose sulfate gel: a phase I safety and colposcopy study. Contraception 64 (2001) 383-391
112. El-Sadr W.M., Mayer K.H., Maslankowsi L., et al. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS 20 (2006) 1109-1116
113. Schwartz J.L., Mauck C., Lai J.J., et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind phase I safety study. Contraception 74 (2006) 133-140
114. Jespers V., Buve A., and van Damme L. Safety trial of the vaginal microbicide cellulose sulfate gel in HIV-positive men. Sex Transm Dis 34 (2007) 519-522
115. Mauck C., Frezieres R., Walsh T., Robergeau K., and Callahan M. Cellulose sulfate: tolerance and acceptability of penile application. Contraception 64 (2001) 377-381
116. Malonza I.M., Mirembe F., Nakabiito C., et al. Expanded phase I safety and acceptability study of 6% cellulose sulfate vaginal gel. AIDS 19 (2005) 2157-2163
117. Neurath A.R., Strick N., and Li Y.Y. Water dispersible microbicidal cellulose acetate phthalate film. BMC Infect Dis 3 (2003) 27
118. Lu H., Zhao Q., Wallace G., et al. Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates. AIDS Res Hum Retroviruses 22 (2006) 411-418
119. Kawamura T., Cohen S.S., Borris D.L., et al. Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med 192 (2000) 1491-1500
120. Fichorova R.N., Zhou F., Ratnam V., et al. Anti-human immunodeficiency virus type 1 microbicide cellulose acetate 1,2-benzenedicarboxylate in a human in vitro model of vaginal inflammation. Antimicrob Agents Chemother 49 (2005) 323-335
121. Neurath A.R., Strick N., Li Y.Y., Lin K., and Jiang S. Design of a "microbicide" for prevention of sexually transmitted diseases using "inactive" pharmaceutical excipients. Biologicals 27 (1999) 11-21
122. Lederman M.M., Veazey R.S., Offord R., et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306 (2004) 485-487
123. Veazey R.S., Klasse P.J., Schader S.M., et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438 (2005) 99-102
124. Mayer K.H., Maslankowski L.A., Gai F., et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 20 (2006) 543-551
125. Schwartz J.L., Kovalevsky G., Lai J.J., et al. A randomized six day safety study of an antiretroviral microbicide candidate UC-781, a non-nucleoside reverse transcriptase inhibitor. Sex Transm Dis 35 (2008) 414-419
126. Maeda K., Nakata H., Ogata H., Koh Y., Miyakawa T., and Mitsuya H. The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection. Curr Opin Pharmacol 4 (2004) 447-452
127. Torre V.S., Marozsan A.J., Albright J.L., et al. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs. J Virol 74 (2000) 4868-4876
128. Kawamura T., Bruse S.E., Abraha A., et al. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. J Virol 78 (2004) 7602-7609
129. Kawamura T., Gulden F.O., Sugaya M., et al. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci USA 100 (2003) 8401-8406
130. Lin P.F., Blair W., Wang T., et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA 100 (2003) 11013-11018
131. Guo Q., Ho H.T., Dicker I., et al. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J Virol 77 (2003) 10528-10536
132. Lu M. Stabilizing peptides and their use in the preparation of stabilized HIV inhibitors. World Intellectual Property Organization Patent WO-04/106364A1. 2004.
133. Bewley C.A., and Otero-Quintero S. The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man(8) D1D3 and Man(9) with nanomolar affinity: implications for binding to the HIV envelope protein gp120. J Am Chem Soc 123 (2001) 3892-3902
134. Bewley C.A. Rapid validation of the overall structure of an internal domain-swapped mutant of the anti-HIV protein cyanovirin-N using residual dipolar couplings. J Am Chem Soc 123 (2001) 1014-1015
135. Tsai C.C., Emau P., Jiang Y., et al. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 19 (2003) 535-541
136. Tsai C.C., Emau P., Jiang Y., et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 20 (2004) 8-11
137. Balzarini J., Van Laethem K., Peumans W.J., et al. Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with n-glycan deletions in their gp120 envelopes. J Virol 80 (2006) 8411-8421
138. Xu Q. Development of a live topical microbicide for women. Microbicides 2008 Conference. New Delhi, India; Feb 24-27, 2008. Abstract 221.
139. Wiysonge C.S., Shey M.S., Shang J., Kongnyuy E.J., and Brocklehurst P. Vaginal microbicides for preventing mother-to-child transmission of HIV infection-no evidence of an effect or evidence of no effect?. S Afr Med J 97 (2007) 530-533
140. Tsai C.C., Follis K.E., Sabo A., et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270 (1995) 1197-1199
141. Balzarini J., Zhang H., Herdewijn P., Johns D., and De Clercq E. Intracellular metabolism and mechanism of antiretrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci USA 88 (1991) 1499-1503
142. Aquaro S., Caliò R., Balzarini J., Bellocchi M.C., Garaci E., and Perno C.F. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res 55 (2002) 209-225
143. Robbins B.L., Srinivas R.V., Kim C., Bischofberger N., and Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 42 (1998) 612-617
144. Otten R.A., Smith D.K., Adams D.R., et al. Efficacy of post exposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 74 (2000) 9771-9775
145. Wainberg M. The prospect for RT inhibitors as topical microbicides. Microbicides 2004 Conference; London, UK; March 28-31, 2004. Abstract MMM-03.
146. Barditch-Crovo P., Deeks S.G., Collier A., et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 45 (2001) 2733-2739
147. Hillier S. Safety and acceptability of daily and coitally dependent use of 1% tenofovir over six months of use. Microbicides 2008 Conference. New Delhi, India; Feb 24-27, 2008. Abstract 655.
148. Schwartz JL, Kashuba A, Rezk N, et al. Preliminary results from a pharmacokinetic study of the candidate vaginal microbicide candidate 1% tenofovir gel. Microbicides 2008 Conference; New Delhi, India; Feb 24-27, 2008. Abstract B011-210.
149. Balzarini J., Pelemans H., Aquaro S., et al. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol Pharmacol 50 (1996) 394-401
150. Borkow G., Barnard J., Nguyen T.M., Belmonte A., Wainberg M.A., and Parniak M.A. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol 71 (1997) 3023-3030
151. Buckheit R.W., Snow M.J., Fliakas-Boltz V., et al. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates. Antimicrob Agents Chemother 41 (1997) 831-837
152. Balzarini J., Naesens L., Verbeken E., et al. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS 12 (1998) 1129-1138
153. Di Fabio S., Van R.J., Giannini G., et al. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 17 (2003) 1597-1604
154. Fletcher P., Kiselyeva Y., Wallace G., et al. The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol 79 (2005) 11179-11186
155. Van H.Y., Michiels J., Van R.J., et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother 48 (2004) 337-339
156. Van H.Y., Vanham G., Michiels J., et al. A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides. Antimicrob Agents Chemother 48 (2004) 3684-3689
157. Zussman A., Lara L., Lara H.H., Bentwich Z., and Borkow G. Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. AIDS 17 (2003) 653-661
158. Hossain M.M., and Parniak M.A. In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1. J Virol 80 (2006) 4440-4446
159. Talwar G.P., Raghuvanshi P., Mishra R., et al. Polyherbal formulations with wide spectrum antimicrobial activity against reproductive tract infections and sexually transmitted pathogens. Am J Reprod Immunol 43 (2000) 144-151
160. Joshi S.N., Katti U., Godbole S., et al. Phase I safety study of Praneem polyherbal vaginal tablet use among HIV-uninfected women in Pune, India. Trans R Soc Trop Med Hyg 99 (2005) 769-774
161. Joglekar N.S., Joshi S.N., Navlakha S.N., Katti U.R., and Mehendale S.M. Acceptability of Praneem polyherbal vaginal tablet among HIV uninfected women and their male partners in Pune India-phase I study. Indian J Med Res 123 (2006) 547-552
162. Josh S.N., Dutta S., Kumar B.K., et al. Expanded safety study of Praneem polyherbal vaginal tablet among HIV-uninfected women in Pune, India: a phase II clinical trial report. Sex Transm Infect 84 (2008) 343-437
163. In: Lagakos S.W., and Gable A.R. (Eds). Methodological challenges in biomedical HIV prevention trials (2008), National Academy of Sciences-The National Academies Press, Washington, DC
164. Pharmaco-Economics Working group of the Microbicide Initiative. The economics of microbicide development: a case for investment (2002), Rockefeller Foundation Microbicide Initiative, New York 27
165. Global Campaign for Microbicides. Funding needs. http://www.global-campaign.org/fundingneeds.htm (accessed Sept 28, 2008).
166. Grufferman S. Complexity and the Hawthorne effect in community trials. Epidemiology 10 (1999) 209-210
167. Bentley M., Morrow K.M., Fullem A., et al. Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam Plann Perspect 32 (2000) 184-188
168. Woodsong C. Covert use of topical microbicides: implications for acceptability and use. Perspect Sex Reprod Health 36 (2004) 127-131
169. Moench TR, Doncel GF, Cone RA. The HEC placebo: designed for "no effect". Microbicides 2004 Conference; London, UK; March 28-31, 2004. Abstract 02609.
170. Tien D., Schnaare R.L., Kang F., et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 21 (2005) 845-853
171. Garg S., Kandarapu R., Vermani K., et al. Development pharmaceutics of microbicide formulations. Part I: preformulation considerations and challenges. AIDS Patient Care STDS 17 (2003) 17-32
172. Terrazas-Aranda K., Van Herrewege Y., Hazuda D., et al. Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection. Antimicrob Agents Chemother 52 (2008) e2544-e2554